Characteristics | Postoperative capecitabine duration | P value | ||
---|---|---|---|---|
0 | ≤ 12 weeks | ≤ 24 weeks | ||
No. of participants | 143 | 79 | 35 | |
Age (years), mean (SD) | 77.69 (4.90) | 73.57 (2.77) | 73.34 (2.99) | < 0.001 |
≥ 70, < 75 | 43 (30.07%) | 46 (58.23%) | 25 (71.43%) | |
≥ 75, < 80 | 43 (30.07%) | 33 (41.77%) | 8 (22.86%) | |
≥ 80 | 57 (39.86%) | 0 (0.00%) | 2 (5.71%) | |
Gender, N (%) | 0.421 | |||
Male | 85 (59.44%) | 54 (68.35%) | 22 (62.86%) | |
Female | 58 (40.56%) | 25 (31.65%) | 13 (37.14%) | |
T stage, N (%) | 0.177 | |||
1–2 | 8 (5.59%) | 2 (2.53%) | 1 (2.86%) | |
3 | 118 (82.52%) | 68 (86.08%) | 25 (71.43%) | |
4 | 17 (11.89%) | 9 (11.39%) | 9 (25.71%) | |
N stage, N (%) | 0.832 | |||
0 | 74 (51.75%) | 36 (45.57%) | 18 (51.43%) | |
1 | 57 (39.86%) | 33 (41.77%) | 14 (40.00%) | |
2 | 12 (8.39%) | 10 (12.66%) | 3 (8.57%) | |
Stage, N (%) | 0.664 | |||
II | 74 (51.75%) | 36 (45.57%) | 18 (51.43%) | |
III | 69 (48.25%) | 43 (54.43%) | 17 (48.57%) | |
Histological type | 0.883 | |||
Common type | 122 (85.31%) | 68 (86.08%) | 31 (88.57%) | |
Special typea | 21 (14.69%) | 11 (13.92%) | 4 (11.43%) | |
CA199, N (%) | 0.232 | |||
Normal | 122 (85.31%) | 60 (76.92%) | 27 (77.14%) | |
Elevated | 21 (14.69%) | 18 (23.08%) | 8 (22.86%) | |
CEA, N (%) | 0.830 | |||
Normal | 92 (64.34%) | 48 (60.76%) | 23 (65.71%) | |
Elevated | 51 (35.66%) | 31 (39.24%) | 12 (34.29%) | |
MMR status | 0.021 | |||
dMMR | 15 (10.49%) | 3 (3.80%) | 2 (5.71%) | |
pMMR | 106 (74.13%) | 51 (64.56%) | 28 (80.00%) | |
Unknown | 22 (15.38%) | 25 (31.65%) | 5 (14.29%) | |
Charlson comorbidity index | < 0.001 | |||
≤ 4 | 88 (61.54%) | 75 (94.94%) | 34 (97.14%) | |
> 4 | 55 (38.46%) | 4 (5.06%) | 1 (2.86%) |